MCID: PRS038
MIFTS: 66

Personality Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Personality Disorder

MalaCards integrated aliases for Personality Disorder:

Name: Personality Disorder 12 29 15
Personality Disorders 55 43 15 72
Character Disorder 12
Personality 17

Classifications:



External Ids:

Disease Ontology 12 DOID:1510
ICD9CM 35 301.8 301.89
ICD10 33 F60 F60.9
UMLS 72 C0029707 C0031212

Summaries for Personality Disorder

MedlinePlus : 43 Personality disorders are a group of mental illnesses. They involve long-term patterns of thoughts and behaviors that are unhealthy and inflexible. The behaviors cause serious problems with relationships and work. People with personality disorders have trouble dealing with everyday stresses and problems. They often have stormy relationships with other people. The cause of personality disorders is unknown. However, genes and childhood experiences may play a role. The symptoms of each personality disorder are different. They can mild or severe. People with personality disorders may have trouble realizing that they have a problem. To them, their thoughts are normal, and they often blame others for their problems. They may try to get help because of their problems with relationships and work. Treatment usually includes talk therapy and sometimes medicine.

MalaCards based summary : Personality Disorder, also known as personality disorders, is related to avoidant personality disorder and schizoid personality disorder, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Fluoxetine and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A disease of mental health that involve long-term patterns of thoughts and behaviors that cause serious problems with relationships and work.

Wikipedia : 75 Personality disorders (PD) are a class of mental disorders characterized by enduring maladaptive... more...

Related Diseases for Personality Disorder

Diseases in the Personality Disorder family:

Multiple Personality Disorder

Diseases related to Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3532)
# Related Disease Score Top Affiliating Genes
1 avoidant personality disorder 35.1 TPH1 SLC6A4 MAOA
2 schizoid personality disorder 34.8 HTR2A HTR1A
3 dependent personality disorder 33.9 MAOB MAOA DRD4
4 intermittent explosive disorder 33.5 SLC6A4 PRL HTR1A
5 phobic disorder 32.2 SLC6A4 MAOA HTR1A COMT
6 hypoactive sexual desire disorder 32.0 HTR2A HTR1A
7 kleine-levin hibernation syndrome 31.7 TPH1 SLC6A3 COMT
8 borderline personality disorder 31.5 TPH2 TPH1 SLC6A4 MAOA HTR2C HTR2A
9 dysthymic disorder 31.3 SLC6A4 MAOA HTR2A
10 agoraphobia 31.2 SLC6A4 MAOA HTR1A
11 impulse control disorder 31.1 DRD4 DRD2 ANKK1
12 antisocial personality disorder 31.0 SLC6A4 SLC6A3 MAOB MAOA HTR1B DRD2
13 social phobia 30.7 SLC6A4 PRL MAOA HTR1A DRD2
14 anorexia nervosa 30.6 SLC6A4 PRL HTR2A COMT BDNF
15 bulimia nervosa 30.6 SLC6A4 HTR2A HTR1B COMT BDNF
16 sexual disorder 30.5 SLC6A4 PRL HTR1A
17 cocaine dependence 30.4 SLC6A4 SLC6A3 DRD2
18 traumatic brain injury 30.4 DRD2 COMT BDNF
19 panic disorder 30.4 TPH2 SLC6A4 MAOA HTR2A HTR1A COMT
20 brain injury 30.4 DRD2 COMT BDNF
21 opiate dependence 30.3 TPH1 SLC6A4 DRD2
22 fibromyalgia 30.3 SLC6A4 PRL HTR2A COMT
23 phobia, specific 30.3 MAOA COMT
24 postpartum depression 30.2 SLC6A4 PRL MAOA COMT BDNF
25 kleptomania 30.2 SLC6A4 MAOA HTR1A
26 eating disorder 30.1 SLC6A4 SLC6A3 HTR2C DRD2 COMT BDNF
27 galactorrhea 30.1 PRL DRD2
28 schizophreniform disorder 30.0 PRL DRD2 COMT
29 conduct disorder 30.0 TPH1 SLC6A4 SLC6A3 MAOA DRD4 DRD2
30 delusional disorder 30.0 DRD4 DRD2
31 depression 29.9 TPH2 TPH1 SLC6A4 MAOA HTR2C HTR2A
32 polysubstance abuse 29.9 DRD2 COMT
33 endogenous depression 29.9 TPH1 SLC6A4 MAOA HTR2A HTR1A BDNF
34 schizoaffective disorder 29.8 SLC6A4 PRL HTR2A DRD2 COMT BDNF
35 atypical depressive disorder 29.8 SLC6A4 MAOB MAOA HTR2A
36 migraine with aura 29.8 SLC6A4 HTR2C DRD2
37 separation anxiety disorder 29.8 SLC6A3 PRL DRD4
38 cocaine abuse 29.7 SLC6A4 SLC6A3 PRL DRD2
39 drug dependence 29.7 SLC6A4 DRD2 BDNF ANKK1
40 nervous system disease 29.7 SLC6A3 MAOB BDNF
41 tardive dyskinesia 29.7 HTR2A DRD2 COMT
42 paraphilia disorder 29.7 PRL MAOB MAOA
43 autism 29.7 SLC6A4 HTR2A HTR1A BDNF AVPR1A
44 substance-induced psychosis 29.7 HTR2A HTR1A DRD2
45 chronic fatigue syndrome 29.7 TPH2 SLC6A4 MAOA HTR2A HTR1A COMT
46 bipolar i disorder 29.6 SLC6A4 HTR2C HTR2A HTR1A COMT BDNF
47 alexithymia 29.6 SLC6A4 HTR1A DRD2 COMT ANKK1
48 bipolar disorder 29.6 TPH1 SLC6A4 SLC6A3 HTR2A HTR1A DRD2
49 paranoid schizophrenia 29.6 TPH2 SLC6A4 MAOA HTR2A COMT BDNF
50 autism spectrum disorder 29.6 TPH2 SLC6A4 HTR2A BDNF AVPR1A

Comorbidity relations with Personality Disorder via Phenotypic Disease Network (PDN): (show all 14)


Acute Cystitis Alzheimer Disease
Anxiety Deficiency Anemia
Dependent Personality Disorder Dysthymic Disorder
Generalized Anxiety Disorder Heart Disease
Hypertension, Essential Hypothyroidism
Major Depressive Disorder Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Schizophreniform Disorder

Graphical network of the top 20 diseases related to Personality Disorder:



Diseases related to Personality Disorder

Symptoms & Phenotypes for Personality Disorder

UMLS symptoms related to Personality Disorder:


photophobia, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances

MGI Mouse Phenotypes related to Personality Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 ALDH2 AVPR1A BDNF COMT DRD2 DRD4
2 homeostasis/metabolism MP:0005376 10.2 ALDH2 AVPR1A BDNF COMT DRD2 DRD4
3 cardiovascular system MP:0005385 10.1 ALDH2 AVPR1A COMT DRD2 HTR1A HTR1B
4 endocrine/exocrine gland MP:0005379 10.07 ALDH2 AVPR1A BDNF COMT DRD2 HTR1B
5 integument MP:0010771 9.91 ALDH2 BDNF DRD2 HTR2C PRL SLC6A3
6 muscle MP:0005369 9.81 ALDH2 AVPR1A DRD2 HTR1B HTR2A HTR2C
7 nervous system MP:0003631 9.8 ALDH2 AVPR1A BDNF COMT DRD2 DRD4
8 taste/olfaction MP:0005394 8.92 BDNF DRD2 SLC6A3 TPH2

Drugs & Therapeutics for Personality Disorder

Drugs for Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 428)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
2
Norepinephrine Approved Phase 4 51-41-2 439260
3
Mirabegron Approved Phase 4 223673-61-8 9865528
4
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
5
Ibuprofen Approved Phase 4 15687-27-1 3672
6
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
7
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
8
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
9
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
10
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
11
Lithium carbonate Approved Phase 4 554-13-2
12
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
13
Haloperidol Approved Phase 4 52-86-8 3559
14
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
15
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
16
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
17
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
18
Liraglutide Approved Phase 4 204656-20-2 44147092
19
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
20
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
21
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
22
Rifaximin Approved, Investigational Phase 4 80621-81-4 46783403 6436173
23
Lactulose Approved Phase 4 4618-18-2 11333
24
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
25
Cycloserine Approved Phase 4 68-41-7 6234 401
26
Nicotine Approved Phase 4 54-11-5 942 89594
27
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
28
Propranolol Approved, Investigational Phase 4 525-66-6 4946
29
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
30
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
31
Naratriptan Approved, Investigational Phase 4 121679-13-8, 143388-64-1 4440
32
Sertraline Approved Phase 4 79617-96-2 68617
33
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
34
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
35
Ornithine Approved, Nutraceutical Phase 4 70-26-8, 3184-13-2 6262
36 Mosapride Investigational Phase 4 112885-41-3
37
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
38 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
39 Adrenergic beta-Agonists Phase 4
40 Solifenacin succinate Phase 4 242478-38-2
41 Adrenergic beta-3 Receptor Agonists Phase 4
42 Bile Acids and Salts Phase 4
43 Cholagogues and Choleretics Phase 4
44 Antipsychotic Agents Phase 4
45 Antimanic Agents Phase 4
46 Dopamine agonists Phase 4
47 Serotonin Antagonists Phase 4
48 Dopamine Antagonists Phase 4
49 Diuretics, Potassium Sparing Phase 4
50 Sodium Channel Blockers Phase 4

Interventional clinical trials:

(show top 50) (show all 1289)
# Name Status NCT ID Phase Drugs
1 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder: a Randomized, Double Blind Clinical Trial. Unknown status NCT00437099 Phase 4 Omacor®;Placebo
2 A Study of Topiramate Augmentation in Serotonin Reuptake Inhibitor (SRI) -Refractory Obsessive Compulsive Disorder Unknown status NCT00182520 Phase 4 Topiramate;placebo
3 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
4 Cost-Effectiveness of Adding Web-Based CBT to Luvox CR for OCD Unknown status NCT00743834 Phase 4 Luvox CR
5 Efficacy of Exposure and Response Prevention(ERP) and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder Unknown status NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
6 Treatment With Escitalopram (Cipralex®) for Adolescents With Obsessive-Compulsive Disorder: Efficacy, Safety, and Changes in Executive Functions, Metacognition, and Regional Brain Activations. Unknown status NCT00708240 Phase 4 Escitalopram
7 Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes: A Prospective Randomized Controlled Trial Unknown status NCT02540707 Phase 4 solifenacin;mirabegron
8 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
9 Brain Mechanisms For Clinical Placebo in Chronic Pain: A Randomized Clinical Trial of Placebo, Active Treatment, and No Treatment in Chronic Back Pain Unknown status NCT02986334 Phase 4 Naproxen;Omeprazole;Placebo
10 Therapeutic Effect of Ursodeoxycholic Acid on Duodenal Permeability and Meal Related Sensory Motor Function in Functional Dyspepsia Patients Unknown status NCT03004118 Phase 4 Placebo Oral Tablet;Ursochol oral tablet
11 Prediction of Individual Treatment Response Based on Brain Changes at the Early Phase of Antidepressant Treatment in Major Depressive Disorder Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
12 Treatment of Primary Mood Disorders in the Comorbidly Ill Completed NCT00178061 Phase 4
13 Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder Completed NCT00634062 Phase 4 Lamotrigine;Placebo
14 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder: The UAB Borderline Rating Scale (BRS) Completed NCT00204347 Phase 4 risperidone
15 Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
16 Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder: Predictors of Change Completed NCT00834834 Phase 4 Fluoxetine;Citalopram
17 Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Completed NCT02194075 Phase 4 Fluvoxamine+Methylphenidate hydrochloride;Fluvoxamine+sugar pill
18 Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder (Randomized, Double-blind, Multi-center Study) Completed NCT00723060 Phase 4 escitalopram
19 Ondansetron Augmentation in Treatment Resistant Obsessive Compulsive Disorder: A Preliminary Single-Blind Prospective Study Completed NCT00796497 Phase 4 ondansetron
20 Ondansetron Augmentation in Treatment-resistant OCD Completed NCT01303536 Phase 4 Ondansetron
21 Pharmacological Augmentation Strategies for Obsessive Compulsive Disorder Patients Non-respondent to First Line Medication Treatment: a Double Blind Placebo Controlled Study Completed NCT00466609 Phase 4 Clomipramine (fluoxetine plus clomipramine);Quetiapine (fluoxetine plus quetiapine);Placebo (fluoxetine plus placebo)
22 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Completed NCT00211744 Phase 4 topiramate
23 Escitalopram for the Treatment of Obsessive Compulsive Disorder Completed NCT00116532 Phase 4 Escitalopram
24 Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial. Completed NCT00564564 Phase 4 Quetiapine;Clomipramine
25 Reclaim® Deep Brain Stimulation Therapy for Obsessive-Compulsive Disorder: Post-Market Clinical Follow-up Study (OCD PMCF) Completed NCT01135745 Phase 4
26 Internet-based Cognitive Behavior Therapy in Combination With D-Cycloserine for Obsessive Compulsive Disorder: A Double Blinded Randomized Controlled Trial Completed NCT01649895 Phase 4 D-Cycloserine;Placebo
27 A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder Completed NCT00994786 Phase 4 pregabalin;Placebo
28 An Long Term Trial on Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder Completed NCT00854919 Phase 4 atypical antipsychotic drug
29 Neurobiology/Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
30 Comparison of Olanzapine and Lamotrigine in the Prevention of Recurrence of Depressive Episode in the Patients With Bipolar Disorders Completed NCT01864551 Phase 4 Lamotrigine;Olanzapine
31 Duloxetine for the Treatment of Obsessive Compulsive Disorder Completed NCT00464698 Phase 4 Duloxetine
32 Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Randomized Open Trial for Any Patient. Completed NCT00680602 Phase 4 SSRI (fluoxetine, sertraline, paroxetine, citalopram)
33 12 Week Prospective Double Blind Placebo Controlled Randomized Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
34 A Placebo Controlled Trial of Amoxicillin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
35 SSRI-Induced Activation Syndrome in Pediatric Obsessive Compulsive Disorder Completed NCT00382291 Phase 4 Regular Titration;Placebo;Slow Titration
36 Double Blind Placebo Controlled Study of Depakote (Divalproex Sodium) in Children With Temper Outbursts and Severe Mood Swings Completed NCT02078596 Phase 4 Divalproex
37 Multimodal Treatment Study of Children With ADHD Completed NCT00000388 Phase 4 Anti-ADHD medication
38 A Pilot Study of Cranial Electrotherapy Stimulation[CES] for Generalized Anxiety Disorder Completed NCT00539357 Phase 4
39 Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD Completed NCT02473185 Phase 4 Methylphenidate
40 Stress, Anxiety and Type A Personality and Analgesics. Impact on Induction Time and Consumption of Analgesics During Cardiac Surgery Completed NCT02756598 Phase 4 Sufentanil I;Sufentanil II;Propofol I;Propofol II
41 Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor Completed NCT02929485 Phase 4 Tolcapone;Placebo;Bromocriptine
42 Associations Between Gene-Polymorphisms, Endo-Phenotypes for Depression and Antidepressive Treatment (AGENDA) Completed NCT00386841 Phase 4 Escitalopram;Placebo
43 Study of the Effects of Tribulus Terrestris on Sexuality in Postmenopausal Women Completed NCT01407445 Phase 4 Placebo;Tribulus terrestris
44 A Comparative Study of Lansoprazole and Mosapride for Functional Dyspepsia: Focus on Difference Between Epigastric Pain Syndrome and Postprandial Distress Syndrome Completed NCT00663897 Phase 4 lansoprazole;mosapride
45 Bio-behavioral Lung Cancer Prevention Program Completed NCT00322205 Phase 4 zyban
46 Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients During Emotional Tasks and With Reference to Controls Completed NCT01109147 Phase 4
47 Depression: The Search for Treatment-Relevant Phenotypes Completed NCT00073697 Phase 4 Escitalopram
48 Health Effects From Removal of Amalgam Restorations in Patients With Symptoms Allegedly Related to Dental Amalgam - A Study of Patients Examined at the Dental Biomaterials Adverse Reaction Unit in 1993 to 1999 Completed NCT00346944 Phase 4
49 The Influence of Appetite-Related Central and Gut Hormones in Modulating Binge Eating Behaviour in Obese and Overweight Healthy Subjects Completed NCT01739049 Phase 4 Liraglutide
50 Depression: The Search for Treatment-Relevant Phenotypes Completed NCT00222820 Phase 4 escitalopram

Search NIH Clinical Center for Personality Disorder

Genetic Tests for Personality Disorder

Genetic tests related to Personality Disorder:

# Genetic test Affiliating Genes
1 Personality Disorder 29

Anatomical Context for Personality Disorder

MalaCards organs/tissues related to Personality Disorder:

41
Brain, Testes, Heart, Cortex, Breast, Amygdala, Eye

Publications for Personality Disorder

Articles related to Personality Disorder:

(show top 50) (show all 18864)
# Title Authors PMID Year
1
Dependency, mood instability, and inconsequence traits for discriminating borderline personality disorder. 38 17
30994782 2019
2
Experience of Occupations among People Living with a Personality Disorder. 38 17
31049046 2019
3
The multiple facets of psychopathy in attack and defense conflicts. 17
31407984 2019
4
The link between rejection sensitivity and borderline personality disorder: A systematic review and meta-analysis. 38
30900278 2019
5
Electroconvulsive therapy in bipolar depression - effectiveness and prognostic factors. 38
31334829 2019
6
Personality disorders and physical comorbidities: a complex relationship. 38
31219842 2019
7
DSM Borderline Criterion Function Across Age-Groups: A Cross-Sectional Mixed-Method Study. 38
30003799 2019
8
Concepts of mental disorders in the United Kingdom: Similarities and differences between the lay public and psychiatrists. 38
31311429 2019
9
Predictors of Symptoms Remission Among Family Caregivers of Individuals With Dementia Receiving REACH VA. 38
30722668 2019
10
CR-19-0950: Event-related responses to alcohol-related stimuli in Mexican-American young adults: Relation to age, gender, comorbidity and "dark side" symptoms. 38
31323376 2019
11
Violent offending in borderline personality disorder and attention deficit/hyperactivity disorder. 38
30844407 2019
12
Out of control? Acting out anger is associated with deficient prefrontal emotional action control in male patients with borderline personality disorder. 38
30553826 2019
13
Feasibility and Acceptability of the Gerontological Personality Disorders Scale (GPS) in General Practice: A Mixed Methods Study. 38
29578809 2019
14
Comparing two domain scoring methods for the Personality Inventory for DSM-5. 38
31233325 2019
15
Obsessive compulsive personality traits: Understanding the chain of pathogenesis from health to disease. 38
31202047 2019
16
Behavioral and electrophysiological responses to fairness norm violations in antisocial offenders. 38
29397410 2019
17
Implications for the Measurement of Psychopathy in the DSM-5 Using the Computerized Adaptive Test of Personality Disorder. 38
29873521 2019
18
Childhood sexual abuse is significantly associated with subsequent sexual offending: New evidence among federal correctional clients. 38
31252352 2019
19
Risk Factors Associated With Inpatient Violence During Medium Security Treatment. 38
27708195 2019
20
Unmet Needs of People with Serious Mental Illness: Perspectives from Certified Peer Specialists. 38
31154551 2019
21
Construct Validity of the McLean Screening Instrument for Borderline Personality Disorder in Two Singaporean Samples. 38
29949444 2019
22
A meta-analysis of treatment as usual for borderline personality disorder. 38
31414854 2019
23
Staff and client perspectives of the Open Borders programme for people with borderline personality disorder. 38
31081282 2019
24
A short screening tool for borderline personality disorder (Short-Bord): Validated by Rasch analysis. 38
31415930 2019
25
Cross-Domain Assessment of Distress Intolerance: Associations With Borderline Personality Disorder Features. 38
30307823 2019
26
Respiratory Sinus Arrhythmia Mediates Links Between Borderline Personality Disorder Symptoms and Both Aggressive and Violent Behavior. 38
30307825 2019
27
Neurophysiological activity following rewards and losses among female adolescents and young adults with borderline personality disorder. 38
31318241 2019
28
Neurocircuitry associated with symptom dimensions at baseline and with change in borderline personality disorder. 38
31302291 2019
29
Predictors of short- and long-term recurrence of suicidal behavior in borderline personality disorder. 38
31155713 2019
30
Ruminative responses to interpersonal precipitants mediate borderline personality disorder features' effects on distress reactivity and recovery in daily life. 38
31392728 2019
31
Resting-state functional connectivity after hydrocortisone administration in patients with post-traumatic stress disorder and borderline personality disorder. 38
31262544 2019
32
Individualized treatment response prediction of dialectical behavior therapy for borderline personality disorder using multimodal magnetic resonance imaging. 38
31414575 2019
33
The experiences of people with borderline personality disorder admitted to acute psychiatric inpatient wards: a meta-synthesis. 38
28686468 2019
34
Low high-density lipoprotein and psychopathology: A review. 38
31369659 2019
35
The association between SYT1-rs2251214 and cocaine use disorder further supports its role in psychiatry. 38
31059723 2019
36
Association of Childhood-Onset Inflammatory Bowel Disease With Risk of Psychiatric Disorders and Suicide Attempt. 38
31424531 2019
37
Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. 38
31311335 2019
38
Editorial: Hoarding and Obsessive-Compulsive Disorder. 38
31108161 2019
39
Suicide ideation and attempts in obsessive-compulsive disorder. 38
31046037 2019
40
Temperament and character in homicidal patients with schizophrenia. 38
31215824 2019
41
Overlap of obsessive-compulsive personality disorder and autism spectrum disorder traits among OCD outpatients: an exploratory study. 38
31375037 2019
42
Theory of Mind (ToM) Performance in High Functioning Autism (HFA) and Schizotypal-Schizoid Personality Disorders (SSPD) Patients. 38
31104261 2019
43
Personality disorder traits in young adults with subclinical obsessive-compulsive symptoms: Not just traits related to obsessive-compulsive personality. 38
31380698 2019
44
A review of psychopathy and Cluster B personality traits and their neural correlates in female offenders. 38
31415792 2019
45
Sexual Violation of Patients by Physicians: A Mixed-Methods, Exploratory Analysis of 101 Cases. 38
28627296 2019
46
Psychometric validation of the Childhood Trauma Questionnaire-Short Form (CTQ-SF) in a Danish clinical sample. 38
31154112 2019
47
Neuroanatomical correlates of personality traits in temporal lobe epilepsy: Findings from the Epilepsy Connectome Project. 38
31387000 2019
48
Tremor Distribution and the Variable Clinical Presentation of Essential Tremor. 38
31422549 2019
49
Relations among maternal withdrawal in infancy, borderline features, suicidality/self-injury, and adult hippocampal volume: A 30-year longitudinal study. 38
31381974 2019
50
Barriers and facilitators to the implementation of a stepped care intervention for personality disorder in mental health services. 38
31411004 2019

Variations for Personality Disorder

Expression for Personality Disorder

Search GEO for disease gene expression data for Personality Disorder.

Pathways for Personality Disorder

Pathways related to Personality Disorder according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.46 PRL HTR2C HTR2A HTR1B HTR1A DRD4
2
Show member pathways
12.9 SLC6A3 MAOB MAOA DRD4 DRD2 COMT
3
Show member pathways
12.86 SLC6A4 SLC6A3 MAOA COMT ALDH2
4 12.43 TPH2 TPH1 HTR1A COMT
6 12.2 HTR1B HTR1A DRD2 BDNF
7 12.01 TPH2 TPH1 SLC6A4 MAOA HTR2A HTR1A
8
Show member pathways
11.87 SLC6A3 MAOB MAOA DRD2 BDNF
9
Show member pathways
11.84 HTR2C HTR2A HTR1B HTR1A DRD4 DRD2
10
Show member pathways
11.8 TPH2 TPH1 MAOB MAOA ALDH2
11 11.7 HTR2C HTR2A DRD2
12
Show member pathways
11.49 MAOB MAOA ALDH2
13
Show member pathways
11.37 TPH2 SLC6A4 SLC6A3 MAOA
14 11.34 TPH2 TPH1 SLC6A4 MAOB MAOA HTR2C
15
Show member pathways
11.24 MAOB MAOA ALDH2
16
Show member pathways
11.04 TPH1 MAOA COMT
17 11 TPH2 TPH1 SLC6A4 MAOA HTR2C HTR2A
18
Show member pathways
10.97 SLC6A4 SLC6A3 MAOA COMT ALDH2
19 10.9 HTR2C HTR2A
20
Show member pathways
10.85 MAOB MAOA COMT ALDH2
21 10.82 MAOB MAOA COMT
22
Show member pathways
10.75 MAOB MAOA ALDH2

GO Terms for Personality Disorder

Cellular components related to Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.91 SLC6A4 SLC6A3 HTR2C HTR2A HTR1B HTR1A
2 axon GO:0030424 9.77 SLC6A3 HTR2A DRD2 COMT BDNF
3 integral component of postsynaptic membrane GO:0099055 9.46 SLC6A4 SLC6A3 HTR2A DRD2
4 dopaminergic synapse GO:0098691 9.4 SLC6A3 DRD2
5 integral component of presynaptic membrane GO:0099056 9.35 SLC6A4 SLC6A3 HTR2A HTR1B DRD2
6 serotonergic synapse GO:0099154 9.32 SLC6A4 HTR1B
7 dendrite GO:0030425 9.23 HTR2C HTR2A HTR1B HTR1A DRD4 DRD2
8 integral component of membrane GO:0016021 10.21 SLC6A4 SLC6A3 MAOB MAOA HTR2C HTR2A

Biological processes related to Personality Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.95 HTR2C HTR2A HTR1B HTR1A DRD4
2 cellular calcium ion homeostasis GO:0006874 9.88 HTR2C HTR2A DRD4
3 response to toxic substance GO:0009636 9.87 SLC6A4 MAOB DRD2
4 locomotory behavior GO:0007626 9.87 SLC6A3 HTR2C DRD2
5 memory GO:0007613 9.86 SLC6A4 HTR2A BDNF
6 social behavior GO:0035176 9.83 SLC6A4 DRD4 AVPR1A
7 positive regulation of fat cell differentiation GO:0045600 9.82 TPH1 HTR2C HTR2A
8 regulation of synaptic vesicle exocytosis GO:2000300 9.82 HTR2A HTR1B DRD2
9 response to cocaine GO:0042220 9.8 SLC6A3 HTR1B DRD2
10 release of sequestered calcium ion into cytosol GO:0051209 9.79 HTR2C HTR2A DRD2
11 feeding behavior GO:0007631 9.76 HTR2C HTR1B DRD2
12 behavioral fear response GO:0001662 9.75 HTR2C HTR1A DRD4
13 activation of phospholipase C activity GO:0007202 9.74 HTR2A BDNF AVPR1A
14 response to organic cyclic compound GO:0014070 9.72 SLC6A3 COMT
15 temperature homeostasis GO:0001659 9.72 HTR2A DRD2
16 response to corticosterone GO:0051412 9.72 MAOB AVPR1A
17 positive regulation of kinase activity GO:0033674 9.72 HTR2A DRD4
18 response to iron ion GO:0010039 9.72 SLC6A3 DRD2
19 negative regulation of protein secretion GO:0050709 9.71 DRD4 DRD2
20 dopamine receptor signaling pathway GO:0007212 9.71 DRD4 DRD2
21 bone remodeling GO:0046849 9.71 TPH1 HTR1B
22 prepulse inhibition GO:0060134 9.71 SLC6A3 DRD2
23 circadian rhythm GO:0007623 9.71 TPH2 TPH1 SLC6A4
24 positive regulation of renal sodium excretion GO:0035815 9.7 DRD2 AVPR1A
25 neurotransmitter biosynthetic process GO:0042136 9.7 SLC6A4 SLC6A3
26 grooming behavior GO:0007625 9.7 DRD2 AVPR1A
27 behavioral response to cocaine GO:0048148 9.7 HTR2A DRD4 DRD2
28 G protein-coupled receptor internalization GO:0002031 9.69 HTR1B DRD2
29 vasoconstriction GO:0042310 9.69 SLC6A4 HTR1B HTR1A
30 regulation of behavior GO:0050795 9.68 HTR1B HTR1A
31 catecholamine metabolic process GO:0006584 9.68 MAOA COMT
32 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.68 DRD4 DRD2
33 negative regulation of voltage-gated calcium channel activity GO:1901386 9.68 DRD4 DRD2
34 monoamine transport GO:0015844 9.67 SLC6A4 SLC6A3
35 behavioral response to ethanol GO:0048149 9.67 DRD4 DRD2
36 aromatic amino acid family metabolic process GO:0009072 9.67 TPH2 TPH1
37 dopamine metabolic process GO:0042417 9.67 DRD4 DRD2 COMT
38 response to ethanol GO:0045471 9.67 SLC6A3 MAOB HTR1B DRD2
39 adenohypophysis development GO:0021984 9.66 SLC6A3 DRD2
40 drinking behavior GO:0042756 9.66 HTR1B DRD2
41 regulation of dopamine metabolic process GO:0042053 9.65 SLC6A3 HTR1A DRD4
42 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.65 HTR2C HTR2A HTR1B HTR1A DRD4
43 sperm ejaculation GO:0042713 9.64 SLC6A4 AVPR1A
44 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.63 HTR2C HTR2A
45 negative regulation of serotonin secretion GO:0014063 9.63 MAOB HTR1B
46 neurotransmitter catabolic process GO:0042135 9.63 MAOB MAOA COMT
47 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.62 HTR2A HTR1B HTR1A DRD4
48 serotonin biosynthetic process GO:0042427 9.61 TPH2 TPH1
49 response to histamine GO:0034776 9.61 DRD4 DRD2
50 serotonin receptor signaling pathway GO:0007210 9.61 HTR2C HTR2A HTR1A

Molecular functions related to Personality Disorder according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.93 TPH2 TPH1 MAOB MAOA ALDH2
2 G protein-coupled receptor activity GO:0004930 9.91 HTR2C HTR2A HTR1B HTR1A DRD4 DRD2
3 neurotransmitter receptor activity GO:0030594 9.65 HTR2C HTR2A HTR1B HTR1A DRD4
4 neurotransmitter:sodium symporter activity GO:0005328 9.55 SLC6A4 SLC6A3
5 G protein-coupled serotonin receptor activity GO:0004993 9.55 HTR2C HTR2A HTR1B HTR1A DRD4
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.52 DRD4 DRD2
7 monoamine transmembrane transporter activity GO:0008504 9.51 SLC6A4 SLC6A3
8 dopamine binding GO:0035240 9.5 SLC6A3 DRD4 DRD2
9 primary amine oxidase activity GO:0008131 9.49 MAOB MAOA
10 dopamine neurotransmitter receptor activity GO:0004952 9.48 DRD4 DRD2
11 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.46 TPH2 TPH1
12 tryptophan 5-monooxygenase activity GO:0004510 9.43 TPH2 TPH1
13 drug binding GO:0008144 9.43 SLC6A3 HTR2C HTR2A HTR1B DRD4 DRD2
14 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.4 HTR2C HTR2A
15 serotonin binding GO:0051378 9.02 SLC6A4 HTR2C HTR2A HTR1B HTR1A

Sources for Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....